These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

410 related articles for article (PubMed ID: 27002325)

  • 41. [Two cases of human epidermal growth factor receptor 2-positive advanced gastric cancer successfully treated with S-1, cisplatin, and trastuzumab combination therapy followed by curative resection].
    Yasuyama A; Mikata S; Soma Y; Yoshikawa Y; Watase C; Kubota M; Miyake Y; Matsuura Y; Kim HM; Murakami M; Hirota M; Morishima H; Matsunami N; Hasegawa J; Miwa H; Nezu R
    Gan To Kagaku Ryoho; 2013 Nov; 40(12):2203-6. PubMed ID: 24394060
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Phase II study of S-1 in combination with trastuzumab for HER2-positive metastatic breast cancer.
    Takashima T; Nakayama T; Yoshidome K; Kawajiri H; Kamigaki S; Tsurutani J; Arai T; Ito T; Komoike Y; Doi T; Masuda N; Miyauchi K; Miyoshi Y; Sakamoto J; Morita S; Taguchi T
    Anticancer Res; 2014 Jul; 34(7):3583-8. PubMed ID: 24982373
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Trastuzumab in combination with docetaxel/cisplatin/S-1 (DCS) for patients with HER2-positive metastatic gastric cancer: feasibility and preliminary efficacy.
    Mitsui Y; Sato Y; Miyamoto H; Fujino Y; Takaoka T; Miyoshi J; Kagawa M; Ohnuma H; Hirakawa M; Kubo T; Osuga T; Sagawa T; Sato Y; Takahashi Y; Katsuki S; Okuda T; Takimoto R; Kobune M; Nobuoka T; Hirata K; Kato J; Takayama T
    Cancer Chemother Pharmacol; 2015 Aug; 76(2):375-82. PubMed ID: 26099968
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Extended safety and efficacy data on S-1 plus cisplatin in patients with untreated, advanced gastric carcinoma in a multicenter phase II study.
    Lenz HJ; Lee FC; Haller DG; Singh D; Benson AB; Strumberg D; Yanagihara R; Yao JC; Phan AT; Ajani JA
    Cancer; 2007 Jan; 109(1):33-40. PubMed ID: 17133415
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [HER2-Positive Advanced Gastric Cancer with Disseminated Intravascular Coagulation and Diffuse Bone Marrow Carcinomatosis Successfully Treated with S-1/Trastuzumab Chemotherapy--A Case Report].
    Senoo S; Mannami T; Tamura T; Fujiwara N; Ikeda G; Komoda M; Ohtawa Y; Fujimoto Y; Sato N; Kambara T; Waku T; Kenmotsu M; Kurimoto E; Okada T; Harita S; Sonobe H
    Gan To Kagaku Ryoho; 2015 Dec; 42(13):2471-5. PubMed ID: 26809307
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Safety and efficacy of trastuzumab administered as a 30-min infusion in patients with HER2-positive advanced gastric cancer.
    Oh SY; Lee S; Huh SJ; Lee J; Kim ST; Park SH; Lim HY; Kang WK; Kang BW; Kim JG; Lee HJ; Kim JH; Kang JH; Kim H
    Cancer Chemother Pharmacol; 2019 Mar; 83(3):501-508. PubMed ID: 30535535
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Randomized phase II trial of S-1 plus irinotecan versus S-1 plus paclitaxel as first-line treatment for advanced gastric cancer (OGSG0402).
    Sugimoto N; Fujitani K; Imamura H; Uedo N; Iijima S; Imano M; Shimokawa T; Kurokawa Y; Furukawa H; Goto M
    Anticancer Res; 2014 Feb; 34(2):851-7. PubMed ID: 24511022
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Combination chemotherapy of S-1 and low-dose twice-weekly cisplatin for advanced and recurrent gastric cancer in an outpatient setting: a retrospective study.
    Tsuji A; Shima Y; Morita S; Uchida M; Okamoto K; Morita M; Horimi T; Shirasaka T
    Anticancer Res; 2008; 28(2B):1433-8. PubMed ID: 18505092
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Efficacy of S-1 plus cisplatin combination chemotherapy in patients with HER2-positive advanced gastric cancer.
    Honma Y; Shimada Y; Takashima A; Iwasa S; Kato K; Hamaguchi T; Yamada Y; Taniguchi H; Sekine S; Kushima R
    Int J Clin Oncol; 2014 Oct; 19(5):863-70. PubMed ID: 24218279
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Phase II study of cetuximab plus S-1/cisplatin therapy in Japanese patients with advanced gastric cancer.
    Yamaguchi K; Fuse N; Komatsu Y; Fujii H; Hironaka S; Omuro Y; Muro K; Yasui H; Ueda S; Nishina T; Watanabe M; Ohtsu A
    Jpn J Clin Oncol; 2021 May; 51(6):879-885. PubMed ID: 33561262
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A phase II study of biweekly S-1 and paclitaxel (SPA) as first-line chemotherapy in patients with metastatic or advanced gastric cancer.
    Jiang H; Qian J; Zhao P; Zhang X; Zheng Y; Mao C; Zheng Y; Chen L; Wang Y; Mou H; Fang W; Teng L; Xu N
    Cancer Chemother Pharmacol; 2015 Jul; 76(1):197-203. PubMed ID: 26013324
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A multi-center phase II study of S-1 plus paclitaxel as first-line therapy for patients with advanced or recurrent unresectable gastric cancer.
    Lee JJ; Kim SY; Chung HC; Lee KH; Song HS; Kang WK; Hong YS; Choi IS; Lee YY; Woo IS; Choi JH
    Cancer Chemother Pharmacol; 2009 May; 63(6):1083-90. PubMed ID: 18813927
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Two cases of unresectable advanced gastric cancer treated with S-1, CDDP and trastuzumab].
    Ogino T; Kawamura M; Tsutsumi K; Sakamoto N; Kodama H; Machida T; Takahashi T; Takanashi S; Nakamura Y; Ishii R
    Gan To Kagaku Ryoho; 2013 Feb; 40(2):237-40. PubMed ID: 23411963
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A multicentre randomised trial comparing weekly paclitaxel + S-1 with weekly paclitaxel + 5-fluorouracil for patients with advanced gastric cancer.
    Huang D; Ba Y; Xiong J; Xu N; Yan Z; Zhuang Z; Yu Z; Wan H; Zhang Y; Deng T; Zheng R; Guo Z; Hu C; Wang M; Yu Z; Yao Y; Meng J
    Eur J Cancer; 2013 Sep; 49(14):2995-3002. PubMed ID: 23810466
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A phase II trial of capecitabine plus cisplatin (XP) for patients with advanced gastric cancer with early relapse after S-1 adjuvant therapy: XParTS-I trial.
    Nishikawa K; Tsuburaya A; Yoshikawa T; Takahashi M; Tanabe K; Yamaguchi K; Yoshino S; Namikawa T; Aoyama T; Rino Y; Kawada J; Tsuji A; Taira K; Kimura Y; Kodera Y; Hirashima Y; Yabusaki H; Hirabayashi N; Fujitani K; Miyashita Y; Morita S; Sakamoto J
    Gastric Cancer; 2018 Sep; 21(5):811-818. PubMed ID: 29488122
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A phase II study of modified docetaxel, cisplatin, and S-1 (mDCS) chemotherapy for unresectable advanced gastric cancer.
    Uemura N; Kikuchi S; Sato Y; Ohnuma H; Okamoto K; Miyamoto H; Hirakawa M; Sagawa T; Fujikawa K; Takahashi Y; Okuda T; Minami S; Takahashi M; Okamoto T; Takada K; Miyanisi K; Takayama T; Kato J
    Cancer Chemother Pharmacol; 2017 Oct; 80(4):707-713. PubMed ID: 28849257
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A Retrospective Comparison of Trastuzumab Plus Cisplatin and Trastuzumab Plus Capecitabine in Elderly HER2-Positive Advanced Gastric Cancer Patients.
    Zhu B; Wu JR; Zhou XP
    Medicine (Baltimore); 2015 Aug; 94(34):e1428. PubMed ID: 26313797
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Efficacy of trastuzumab beyond progression in HER2 positive advanced gastric cancer: a multicenter prospective observational cohort study.
    Li Q; Jiang H; Li H; Xu R; Shen L; Yu Y; Wang Y; Cui Y; Li W; Yu S; Liu T
    Oncotarget; 2016 Aug; 7(31):50656-50665. PubMed ID: 27409420
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Phase II study of trastuzumab with modified docetaxel, cisplatin, and 5 fluorouracil in metastatic HER2-positive gastric cancer.
    Mondaca S; Margolis M; Sanchez-Vega F; Jonsson P; Riches JC; Ku GY; Hechtman JF; Tuvy Y; Berger MF; Shah MA; Kelsen DP; Ilson DH; Yu K; Goldberg Z; Epstein AS; Desai A; Chung V; Chou JF; Capanu M; Solit DB; Schultz N; Janjigian YY
    Gastric Cancer; 2019 Mar; 22(2):355-362. PubMed ID: 30088161
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Phase I/II trial of chemoradiotherapy with concurrent S-1 and cisplatin for clinical stage II/III esophageal carcinoma (JCOG 0604).
    Tahara M; Fuse N; Mizusawa J; Sato A; Nihei K; Kanato K; Kato K; Yamazaki K; Muro K; Takaishi H; Boku N; Ohtsu A
    Cancer Sci; 2015 Oct; 106(10):1414-20. PubMed ID: 26250827
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.